| __timestamp | Alkermes plc | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 17986000 |
| Thursday, January 1, 2015 | 311558000 | 32480000 |
| Friday, January 1, 2016 | 374130000 | 68081000 |
| Sunday, January 1, 2017 | 421578000 | 169906000 |
| Monday, January 1, 2018 | 526408000 | 248932000 |
| Tuesday, January 1, 2019 | 599449000 | 354100000 |
| Wednesday, January 1, 2020 | 538827000 | 433300000 |
| Friday, January 1, 2021 | 560977000 | 583300000 |
| Saturday, January 1, 2022 | 605747000 | 752700000 |
| Sunday, January 1, 2023 | 689751000 | 887600000 |
| Monday, January 1, 2024 | 645238000 | 1007200000 |
Data in motion
In the competitive landscape of biopharmaceuticals, understanding the financial strategies of industry leaders is crucial. Over the past decade, from 2014 to 2023, Neurocrine Biosciences, Inc. and Alkermes plc have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Neurocrine Biosciences, Inc. has seen a staggering increase of nearly 4,800% in SG&A expenses, starting from a modest $18 million in 2014 to an impressive $888 million in 2023. In contrast, Alkermes plc's expenses have grown by approximately 245%, from $200 million to $690 million over the same period. This divergence highlights Neurocrine's aggressive expansion and investment in administrative capabilities, while Alkermes maintains a steady growth trajectory. These insights provide a window into the strategic priorities of these companies, reflecting their commitment to innovation and market presence.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Alkermes plc
Comparing SG&A Expenses: Alkermes plc vs Alpine Immune Sciences, Inc. Trends and Insights
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights